Squarepoint
ADAP

Squarepoint’s Adaptimmune Therapeutics ADAP Stock Holding History

Squarepoint’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,563
Closed -$8.92K – 4491
2024
Q4 		$8.92K Buy
+16,563
New +$12.1K ﹤0.01% 4958
2022
Q2 		– Sell
-10,800
Closed -$22K – 2826
2022
Q1 		$22K Sell
10,800
-31,589
-75% -$85.3K ﹤0.01% 2712
2021
Q4 		$159K Buy
42,389
+10,508
+33% +$47.8K ﹤0.01% 2792
2021
Q3 		$165K Buy
31,881
+17,884
+128% +$80.2K ﹤0.01% 2559
2021
Q2 		$60K Sell
13,997
-24,216
-63% -$118K ﹤0.01% 3088
2021
Q1 		$203K Sell
38,213
-17,487
-31% -$100K ﹤0.01% 2695
2020
Q4 		$300K Sell
55,700
-7,585
-12% -$41.2K ﹤0.01% 2201
2020
Q3 		$505K Buy
+63,285
New +$554K 0.01% 1428
2020
Q2 		– Sell
-12,552
Closed -$34K – 2186
2020
Q1 		$34K Buy
+12,552
New +$41.7K ﹤0.01% 1747
2019
Q1 		– Sell
-108,100
Closed -$622K – 2108
2018
Q4 		$622K Buy
+108,100
New +$798K 0.01% 1143
2018
Q3 		– Sell
-50,200
Closed -$596K – 1950
2018
Q2 		$596K Buy
50,200
+8,700
+21% +$108K 0.01% 1103
2018
Q1 		$466K Buy
41,500
+15,300
+58% +$134K 0.01% 1116
2017
Q4 		$175K Buy
26,200
+8,646
+49% +$66.8K ﹤0.01% 1832
2017
Q3 		$144K Buy
+17,554
New +$110K ﹤0.01% 1460

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's ADAP Position: Q1 2025 in Review

Squarepoint sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 16,563 shares — an estimated $8.92K sold.

Squarepoint first reported a position in ADAP in Q3 2017 and held it in 14 quarters. The position peaked at $622K in Q4 2018. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Squarepoint reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Squarepoint sold 16,563 Adaptimmune Therapeutics shares in Q1 2025, an estimated $8.92K.
  • Squarepoint first reported a position in Adaptimmune Therapeutics in Q3 2017 and held it in 14 quarters.
  • Squarepoint's Adaptimmune Therapeutics position peaked at $622K in Q4 2018.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.